Announcement • Apr 23
Winning Health Technology Group Co., Ltd. (SZSE:300253) announces an Equity Buyback for CNY 50 million worth of its shares. Winning Health Technology Group Co., Ltd. (SZSE:300253) announces a share repurchase program. Under the program, the company will repurchase up to CNY 50 million worth of its shares. The shares will be repurchased at no more than CNY 13.14 per share. The repurchased shares will be cancelled to reduce registered share capital of the company. The repurchases will be funded from company's own funds. The program is subject to shareholders approval. The program will be valid for 12 months after the approval of shareholders. Reported Earnings • Apr 15
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥0.17 loss per share (down from CN¥0.041 profit in FY 2024). Revenue: CN¥2.11b (down 24% from FY 2024). Net loss: CN¥373.9m (down CN¥461.8m from profit in FY 2024). Revenue missed analyst estimates by 26%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Apr 15
Winning Health Technology Group Co., Ltd., Annual General Meeting, May 13, 2026 Winning Health Technology Group Co., Ltd., Annual General Meeting, May 13, 2026, at 14:30 China Standard Time. Location: 16F, No. 9, Lane 99, Shouyang Road, Jing'an Diatrict, Shanghai China Announcement • Mar 31
Winning Health Technology Group Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Winning Health Technology Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Price Target Changed • Feb 09
Price target decreased by 9.1% to CN¥10.72 Down from CN¥11.80, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of CN¥10.66. Stock is up 15% over the past year. The company is forecast to post earnings per share of CN¥0.16 for next year compared to CN¥0.041 last year. New Risk • Jan 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Dec 31
Winning Health Technology Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 15, 2026 Winning Health Technology Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 15, 2026 Reported Earnings • Oct 28
Third quarter 2025 earnings released: CN¥0.056 loss per share (vs CN¥0.057 profit in 3Q 2024) Third quarter 2025 results: CN¥0.056 loss per share (down from CN¥0.057 profit in 3Q 2024). Revenue: CN¥456.7m (down 34% from 3Q 2024). Net loss: CN¥123.4m (down 199% from profit in 3Q 2024). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Winning Health Technology Group Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Winning Health Technology Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Reported Earnings • Aug 23
Second quarter 2025 earnings released: CN¥0.056 loss per share (vs CN¥0.006 profit in 2Q 2024) Second quarter 2025 results: CN¥0.056 loss per share (down from CN¥0.006 profit in 2Q 2024). Revenue: CN¥494.2m (down 32% from 2Q 2024). Net loss: CN¥123.3m (down CN¥136.8m from profit in 2Q 2024). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Announcement • Jul 02
Winning Health Technology Group Co., Ltd. to Report First Half, 2025 Results on Aug 27, 2025 Winning Health Technology Group Co., Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 Declared Dividend • May 31
Dividend reduced to CN¥0.015 Dividend of CN¥0.015 is 25% lower than last year. Ex-date: 4th June 2025 Payment date: 4th June 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 42%. Cash payout ratio: 18%. Major Estimate Revision • May 01
Consensus EPS estimates fall by 27% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥3.11b to CN¥3.08b. EPS estimate also fell from CN¥0.225 per share to CN¥0.165 per share. Net income forecast to grow 428% next year vs 29% growth forecast for Healthcare Services industry in China. Consensus price target up from CN¥9.52 to CN¥11.38. Share price rose 8.0% to CN¥10.24 over the past week. Price Target Changed • Apr 23
Price target increased by 8.9% to CN¥10.02 Up from CN¥9.20, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of CN¥9.78. Stock is up 43% over the past year. The company is forecast to post earnings per share of CN¥0.17 for next year compared to CN¥0.041 last year. Announcement • Apr 22
Winning Health Technology Group Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Winning Health Technology Group Co., Ltd. announced on 21 April 2025 the profit distribution proposal for the year 2024 as final cash dividend/10 shares (tax included) of CNY 0.15000000. New Risk • Apr 20
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.2% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.2% net profit margin). Reported Earnings • Apr 20
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.041 (down from CN¥0.17 in FY 2023). Revenue: CN¥2.78b (down 12% from FY 2023). Net income: CN¥87.9m (down 75% from FY 2023). Profit margin: 3.2% (down from 11% in FY 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • Apr 20
Winning Health Technology Group Co., Ltd., Annual General Meeting, May 12, 2025 Winning Health Technology Group Co., Ltd., Annual General Meeting, May 12, 2025, at 14:30 China Standard Time. Location: 16F, No. 9, Lane 99, Shouyang Road, Jing'an Diatrict, Shanghai China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥8.71, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 18x in the Healthcare Services industry in Asia. Total returns to shareholders of 5.1% over the past three years. Announcement • Mar 31
Winning Health Technology Group Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Winning Health Technology Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥11.03, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 19x in the Healthcare Services industry in Asia. Negligible returns to shareholders over past three years. New Risk • Feb 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥7.84, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 21x in the Healthcare Services industry in Asia. Total loss to shareholders of 34% over the past three years. Announcement • Dec 31
Winning Health Technology Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025 Winning Health Technology Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025 Price Target Changed • Nov 04
Price target increased by 13% to CN¥8.83 Up from CN¥7.84, the current price target is an average from 4 analysts. New target price is 18% above last closing price of CN¥7.50. Stock is down 4.2% over the past year. The company is forecast to post earnings per share of CN¥0.20 for next year compared to CN¥0.17 last year. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.057 (vs CN¥0.064 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.057 (down from CN¥0.064 in 3Q 2023). Revenue: CN¥689.6m (down 2.8% from 3Q 2023). Net income: CN¥124.5m (down 8.3% from 3Q 2023). Profit margin: 18% (down from 19% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥7.09, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 22x in the Healthcare Services industry in Asia. Total loss to shareholders of 48% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Large one-off items impacting financial results. Announcement • Sep 30
Winning Health Technology Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Winning Health Technology Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥6.29, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Healthcare Services industry in Asia. Total loss to shareholders of 56% over the past three years. Price Target Changed • Sep 02
Price target decreased by 9.5% to CN¥8.14 Down from CN¥8.99, the current price target is an average from 5 analysts. New target price is 56% above last closing price of CN¥5.23. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥0.26 for next year compared to CN¥0.17 last year. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.037 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.006 (down from CN¥0.037 in 2Q 2023). Revenue: CN¥729.3m (down 1.8% from 2Q 2023). Net income: CN¥13.5m (down 83% from 2Q 2023). Profit margin: 1.9% (down from 11% in 2Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 28% per year. Announcement • Jun 29
Winning Health Technology Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Winning Health Technology Group Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • May 31
Dividend increased to CN¥0.02 Dividend of CN¥0.02 is 100% higher than last year. Ex-date: 4th June 2024 Payment date: 4th June 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.9%. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.008 (vs CN¥0.03 loss in 1Q 2023) First quarter 2024 results: EPS: CN¥0.008 (up from CN¥0.03 loss in 1Q 2023). Revenue: CN¥494.5m (up 10% from 1Q 2023). Net income: CN¥16.6m (up CN¥80.2m from 1Q 2023). Profit margin: 3.4% (up from net loss in 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 20
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.17 (up from CN¥0.051 in FY 2022). Revenue: CN¥3.16b (up 2.3% from FY 2022). Net income: CN¥358.0m (up 230% from FY 2022). Profit margin: 11% (up from 3.5% in FY 2022). Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) also missed analyst estimates by 2.9%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Announcement • Apr 20
Winning Health Technology Group Co., Ltd., Annual General Meeting, May 10, 2024 Winning Health Technology Group Co., Ltd., Annual General Meeting, May 10, 2024, at 14:30 China Standard Time. Location: 16F, No. 9, Lane 99, Shouyang Road, Jing'an District, Shanghai China Price Target Changed • Apr 03
Price target increased by 12% to CN¥9.08 Up from CN¥8.08, the current price target is an average from 4 analysts. New target price is 28% above last closing price of CN¥7.08. Stock is down 50% over the past year. The company is forecast to post earnings per share of CN¥0.17 for next year compared to CN¥0.051 last year. Announcement • Mar 30
Winning Health Technology Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Winning Health Technology Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Announcement • Dec 29
Winning Health Technology Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024 Winning Health Technology Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 13, 2024 Price Target Changed • Nov 10
Price target decreased by 7.5% to CN¥9.29 Down from CN¥10.04, the current price target is an average from 6 analysts. New target price is 19% above last closing price of CN¥7.81. Stock is down 18% over the past year. The company is forecast to post earnings per share of CN¥0.16 for next year compared to CN¥0.051 last year. Reported Earnings • Oct 26
Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations Third quarter 2023 results: EPS: CN¥0.064 (up from CN¥0.034 in 3Q 2022). Revenue: CN¥709.1m (down 8.5% from 3Q 2022). Net income: CN¥135.7m (up 86% from 3Q 2022). Profit margin: 19% (up from 9.4% in 3Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Major Estimate Revision • Aug 24
Consensus revenue estimates fall by 10% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥3.77b to CN¥3.39b. EPS estimate fell from CN¥0.21 to CN¥0.113 per share. Net income forecast to grow 584% next year vs 35% growth forecast for Healthcare Services industry in China. Consensus price target down from CN¥12.22 to CN¥10.34. Share price fell 3.8% to CN¥7.01 over the past week. Reported Earnings • Aug 18
Second quarter 2023 earnings: Revenues and EPS in line with analyst expectations Second quarter 2023 results: EPS: CN¥0.037 (up from CN¥0.016 in 2Q 2022). Revenue: CN¥742.7m (up 14% from 2Q 2022). Net income: CN¥80.1m (up 128% from 2Q 2022). Profit margin: 11% (up from 5.4% in 2Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Announcement • Jul 01
Winning Health Technology Group Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023 Winning Health Technology Group Co., Ltd. announced that they will report first half, 2023 results on Aug 18, 2023 Announcement • Jun 09
Winning Health Technology Group Co., Ltd. Announces Final Dividend Implementation on Share A for 2022, Payable on June 15, 2023 Winning Health Technology Group Co., Ltd. announced implementation of final Cash dividend of 10 shares (tax included) of CNY 0.10000000 on A shares for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023. Price Target Changed • May 09
Price target increased by 8.5% to CN¥12.35 Up from CN¥11.38, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CN¥11.77. Stock is up 39% over the past year. The company is forecast to post earnings per share of CN¥0.21 for next year compared to CN¥0.051 last year. Reported Earnings • Apr 19
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.051 (down from CN¥0.18 in FY 2021). Revenue: CN¥3.09b (up 13% from FY 2021). Net income: CN¥108.4m (down 71% from FY 2021). Profit margin: 3.5% (down from 14% in FY 2021). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 70%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 14% per year. Price Target Changed • Nov 25
Price target increased to CN¥10.04 Up from CN¥9.28, the current price target is an average from 6 analysts. New target price is 14% above last closing price of CN¥8.84. Stock is down 41% over the past year. The company is forecast to post earnings per share of CN¥0.20 for next year compared to CN¥0.18 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jinfeng Feng was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Nov 02
Consensus EPS estimates fall by 62% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥3.33b to CN¥3.23b. EPS estimate also fell from CN¥0.21 per share to CN¥0.08 per share. Net income forecast to grow 99% next year vs 32% growth forecast for Healthcare Services industry in China. Consensus price target of CN¥9.46 unchanged from last update. Share price was steady at CN¥9.69 over the past week. Reported Earnings • Oct 27
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: EPS: CN¥0.034 (down from CN¥0.07 in 3Q 2021). Revenue: CN¥775.0m (up 4.9% from 3Q 2021). Net income: CN¥73.1m (down 51% from 3Q 2021). Profit margin: 9.4% (down from 20% in 3Q 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 9% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥8.14, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 31x in the Healthcare Services industry in Asia. Total loss to shareholders of 36% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥3.52 per share. Reported Earnings • Aug 28
Second quarter 2022 earnings released: EPS: CN¥0.016 (vs CN¥0.046 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.016 (down from CN¥0.046 in 2Q 2021). Revenue: CN¥650.4m (down 4.3% from 2Q 2021). Net income: CN¥35.1m (down 64% from 2Q 2021). Profit margin: 5.4% (down from 14% in 2Q 2021). The decrease in margin was primarily driven by higher expenses. Over the next year, revenue is forecast to grow 35%, compared to a 19% growth forecast for the Healthcare Services industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Jul 09
Winning Health Technology Group Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on July 15, 2022 Winning Health Technology Group Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.20000000 on A shares for the year 2021. Record date is July 14, 2022. Ex-date is July 15, 2022. Payment date is July 15, 2022. Announcement • May 28
Winning Health Technology Group Co., Ltd. Announces Final Dividend for 2021 Winning Health Technology Group Co., Ltd. held its Annual General Meeting of 2021 on 25 May 2022, announced cash dividend/10 shares (tax included) of CNY 0.20000000 for 2021. Major Estimate Revision • Apr 29
Consensus EPS estimates fall by 23% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥3.60b to CN¥3.37b. EPS estimate also fell from CN¥0.36 per share to CN¥0.28 per share. Net income forecast to grow 72% next year vs 39% growth forecast for Healthcare Services industry in China. Consensus price target down from CN¥15.54 to CN¥11.04. Share price rose 2.7% to CN¥7.95 over the past week. Price Target Changed • Apr 27
Price target decreased to CN¥11.04 Down from CN¥15.54, the current price target is an average from 7 analysts. New target price is 43% above last closing price of CN¥7.70. Stock is down 49% over the past year. The company is forecast to post earnings per share of CN¥0.34 for next year compared to CN¥0.18 last year. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: CN¥0.015 (up from CN¥0.007 in 1Q 2021). Revenue: CN¥445.5m (up 29% from 1Q 2021). Net income: CN¥31.8m (up 122% from 1Q 2021). Profit margin: 7.1% (up from 4.2% in 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 34%. Over the next year, revenue is forecast to grow 26%, compared to a 18% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jinfeng Feng was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 26
Winning Health Technology Group Co., Ltd. Proposes Final Dividend for 2021 Winning Health Technology Group Co., Ltd. proposed a final dividend of cash dividend/10 shares (tax included): CNY 0.20000000 for 2021. Buying Opportunity • Apr 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 43%. The fair value is estimated to be CN¥11.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 60% in 2 years. Earnings is forecast to grow by 73% in the next 2 years. Buying Opportunity • Mar 15
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 38%. The fair value is estimated to be CN¥11.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years. Major Estimate Revision • Jan 28
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from CN¥2.94b to CN¥2.89b. EPS estimate also fell from CN¥0.29 per share to CN¥0.26 per share. Net income forecast to grow 31% next year vs 38% growth forecast for Healthcare Services industry in China. Consensus price target down from CN¥16.79 to CN¥15.54. Share price fell 23% to CN¥11.51 over the past week. Price Target Changed • Jan 26
Price target decreased to CN¥15.54 Down from CN¥16.79, the current price target is an average from 8 analysts. New target price is 31% above last closing price of CN¥11.84. Stock is down 21% over the past year. The company is forecast to post earnings per share of CN¥0.27 for next year compared to CN¥0.23 last year. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 21% share price decline to CN¥12.10, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 35x in the Healthcare Services industry in Asia. Total returns to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.74 per share. Price Target Changed • Nov 02
Price target decreased to CN¥15.79 Down from CN¥18.14, the current price target is an average from 7 analysts. New target price is 21% above last closing price of CN¥13.00. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥0.29 for next year compared to CN¥0.23 last year. Price Target Changed • Oct 29
Price target decreased to CN¥17.39 Down from CN¥19.33, the current price target is an average from 7 analysts. New target price is 37% above last closing price of CN¥12.65. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥0.29 for next year compared to CN¥0.23 last year. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.061 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥738.6m (up 28% from 3Q 2020). Net income: CN¥148.1m (up 15% from 3Q 2020). Profit margin: 20% (down from 22% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 29
Second quarter 2021 earnings released: EPS CN¥0.046 (vs CN¥0.029 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥679.7m (up 32% from 2Q 2020). Net income: CN¥97.3m (up 55% from 2Q 2020). Profit margin: 14% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 21
Full year 2020 earnings released: EPS CN¥0.23 (vs CN¥0.19 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CN¥2.27b (up 19% from FY 2019). Net income: CN¥491.1m (up 23% from FY 2019). Profit margin: 22% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 21% per year. Announcement • Mar 09
Winning Health Technology Group Co., Ltd. to Report Fiscal Year 2020 Results on Apr 21, 2021 Winning Health Technology Group Co., Ltd. announced that they will report fiscal year 2020 results on Apr 21, 2021 Price Target Changed • Mar 05
Price target lowered to CN¥20.45 Down from CN¥22.76, the current price target is an average from 10 analysts. The new target price is 7.9% above the current share price of CN¥18.95. As of last close, the stock is down 2.8% over the past year. Announcement • Feb 26
Winning Health Technology Group Co., Ltd. Announces Board Appointments Winning Health Technology Group Co., Ltd. at its extraordinary general meeting held on February 24, 2021, approved appointment of Zhou Wei; Liu Ning; WANG TAO; and Jin Mao as non-independent directors and appointment of Wang Weisong and Feng Jinfeng as independent directors. Is New 90 Day High Low • Feb 18
New 90-day high: CN¥17.90 The company is up 8.0% from its price of CN¥16.54 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare Services industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥8.98 per share. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥14.86 The company is down 27% from its price of CN¥20.26 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 26% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥9.77 per share. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥14.95 The company is down 24% from its price of CN¥19.66 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥9.57 per share. Is New 90 Day High Low • Dec 12
New 90-day low: CN¥15.54 The company is down 17% from its price of CN¥18.71 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥9.59 per share. Is New 90 Day High Low • Nov 17
New 90-day low: CN¥16.63 The company is down 19% from its price of CN¥20.43 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥7.97 per share. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥17.79 The company is down 23% from its price of CN¥23.08 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥8.16 per share. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥328.8m, down 14% from the prior year. Total revenue was CN¥2.08b over the last 12 months, up 22% from the prior year. Announcement • Oct 27
Suqian Jingdong Tianning Health Technology Co., Ltd. and Wuxi AppTec Phase I Investment Enterprise (Limited Partnership) completed the acquisition of 8.6% stake in Shanghai Kingstar Winning Software Technology Co., Ltd. from Zhao Menghai and Winning Health Technology Group Co., Ltd. (SZSE:300253). Suqian Jingdong Tianning Health Technology Co., Ltd. and Wuxi AppTec Phase I Investment Enterprise (Limited Partnership) agreed to acquire 8.6% stake in Shanghai Kingstar Winning Software Technology Co., Ltd. from Zhao Menghai and Winning Health Technology Group Co., Ltd. (SZSE:300253) for CNY 150 million on October 12, 2020. The president office of Winning Health Technology Group Co., Ltd. ha approved the transaction. As of June 30, 2020, Shanghai Kingstar Winning Software Technology Co., Ltd. has reported total assets of CNY 152.33 million and net assets of CNY 135.64 million.
Suqian Jingdong Tianning Health Technology Co., Ltd. and Wuxi AppTec Phase I Investment Enterprise (Limited Partnership) completed the acquisition of 8.6% stake in Shanghai Kingstar Winning Software Technology Co., Ltd. from Zhao Menghai and Winning Health Technology Group Co., Ltd. (SZSE:300253) on October 12, 2020. Announcement • Aug 11
Winning Health Technology Group Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Winning Health Technology Group Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020